Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

February 25, 2014

Primary Completion Date

January 23, 2015

Study Completion Date

October 26, 2016

Conditions
HIVHBV
Interventions
DRUG

E/C/F/TAF

E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food

Trial Locations (24)

20009

Whitman Walker Health, Washington D.C.

32960

AIDS Research and Treatment Center of the Treasure Coast, Vero Beach

33139

AIDS Health Foundation/WPA, Miami Beach

33316

Gary J Richmond M.D.,P.A., Fort Lauderdale

33401

Triple O Research Institute PA, West Palm Beach

33765

Barry M. Rodwick MD, Clearwater

34982

Midway Immunology and Research Center, Ft. Pierce

48072

Be Well Medical Center PC, Berkley

63139

Southampton Healthcare, Inc., St Louis

64111

KC Care Clinic, Kansas City

75246

North Texas Infectious Diseases Consultants, Dallas

77004

Therapeutic Concepts, Houston

77098

Gordon E. Crofoot MD PA, Houston

78705

Central Texas Clinical Research, Austin

85012

Spectrum Medical Group, Phoenix

87505

Southwest CARE Center, Santa Fe

90036

Peter J. Ruane MD, Inc., Los Angeles

90069

Anthony Mills MD, Inc, Los Angeles

90211

AHF Research Center, Beverly Hills

98104

Peter Shalit MD, Seattle

1628655

Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku

Unknown

St. Hope Foundation, Bellaire

M5G 2N2

University Health Network/Toronto General Hospital, Toronto

M5G1K2

Maple Leaf Research/Maple Leaf Medical Clinic, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY